Risk for nonscarring hair loss increased in association with GLP-1 receptor agonist useRisk for nonscarring hair loss increased in association with GLP-1 receptor agonist use
The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the American Academy of Dermatology. The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, Read More
Neighborhood factors related to financial stress are linked to worse breast cancer outcomesNeighborhood factors related to financial stress are linked to worse breast cancer outcomes
Research published in JAMA Network Open connects multiple residential factors generally associated with financial strain, such as high housing costs and crowded households, to worse overall outcomes among breast cancer survivors. Led by investigators at VCU Massey Comprehensive Cancer Center, the findings could help inform innovative strategies to increase health care access and ease economic stress for a variety of patients in need.
Geographic Analysis of Neighborhood Exposome and Breast Cancer SurvivalGeographic Analysis of Neighborhood Exposome and Breast Cancer Survival
This cohort study uses a geographically sensitive neighborhood exposome–wide association study analytic framework to identify which of the myriad components of the neighborhood exposome are associated with survival in patients with breast cancer and the relevant geographic scale of each component.
Novel biomarker predicts chemotherapy response in triple-negative breast cancerNovel biomarker predicts chemotherapy response in triple-negative breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to better account for changes in gene expression within tumors relative to their unique microenvironments. This approach outperformed current methods for predicting chemotherapy response in patients with triple-negative breast cancer (TNBC).
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting FlopGLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop
(MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill) An $80-per-month produce prescription subsidy failed to improve cardiometabolic health… (MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition Read More
Navigating Difficult Questions in Breast Cancer CareNavigating Difficult Questions in Breast Cancer Care
(MedPage Today) — In “Beyond Diagnosis: Breast Cancer,” Cleveland Clinic oncologist Tiffany Onger, MD, and host John Mangels continue their conversations on communicating effectively and empathetically with patients across the breast cancer care…
Taking the next shot: GLP-1 research and the new era of weight lossTaking the next shot: GLP-1 research and the new era of weight loss
Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are now taking medications like Ozempic or Wegovy for weight loss or chronic conditions, and use is expected to keep rising. Soaring in popularity, GLP-1 medications—from Read More
STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and moreSTAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding because that oh-so-familiar routine of meetings, online calls, and deadlines has predictably returned. But what can you do? The world keeps spinning no matter how much we push back. So time to get on with it. Please Read More
STAT+: As China’s drug industry races ahead, its GLP-1 race is accelerating tooSTAT+: As China’s drug industry races ahead, its GLP-1 race is accelerating too
For American and European drugmakers, the story of China today is one of a fast-developing market — one producing not only “me too” therapies but increasingly novel medications as well. And to understand what these shifts might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs, in particular. Earlier this Read More
Researchers identify key mechanism driving progression of fatty liver disease to cancerResearchers identify key mechanism driving progression of fatty liver disease to cancer
According to recent reports from the Korean government, the incidence of alcoholic liver disease—previously the leading indication for liver transplantation—has been decreasing. This trend initially raised expectations that the medical burden of liver transplantation and liver-related mortality would decline. However, the current reality does not reflect this expectation. In addition, fatty liver disease is also increasing steadily due to modern lifestyle factors, and projections indicate that the demand for liver transplantation will continue to rise, with fatty liver-related cases increasingly replacing those caused by alcoholic liver disease.